Brown Advisory’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $477K | Sell |
11,180
-9,120
| -45% | -$495K | ﹤0.01% | 1148 |
|
|
2026
Q1 | $1.27M | Buy |
20,300
+2,326
| +13% | +$186K | ﹤0.01% | 777 |
|
|
2025
Q4 | $1.71M | Sell |
17,974
-2,153
| -11% | -$211K | ﹤0.01% | 716 |
|
|
2025
Q3 | $1.97M | Buy |
20,127
+543
| +3% | +$56.2K | ﹤0.01% | 674 |
|
|
2025
Q2 | $2.1M | Buy |
19,584
+3,571
| +22% | +$361K | ﹤0.01% | 648 |
|
|
2025
Q1 | $1.62M | Sell |
16,013
-417
| -3% | -$42K | ﹤0.01% | 669 |
|
|
2024
Q4 | $1.47M | Sell |
16,430
-1,084
| -6% | -$95.4K | ﹤0.01% | 722 |
|
|
2024
Q3 | $1.47M | Sell |
17,514
-825
| -4% | -$65K | ﹤0.01% | 703 |
|
|
2024
Q2 | $1.41M | Buy |
18,339
+3,658
| +25% | +$268K | ﹤0.01% | 695 |
|
|
2024
Q1 | $1.01M | Buy |
14,681
+2,143
| +17% | +$138K | ﹤0.01% | 778 |
|
|
2023
Q4 | $725K | Buy |
12,538
+11
| +0.1% | +$587 | ﹤0.01% | 841 |
|
|
2023
Q3 | $661K | Sell |
12,527
-993
| -7% | -$52.1K | ﹤0.01% | 840 |
|
|
2023
Q2 | $731K | Sell |
13,520
-2,966
| -18% | -$155K | ﹤0.01% | 816 |
|
|
2023
Q1 | $825K | Buy |
16,486
+2,559
| +18% | +$121K | ﹤0.01% | 804 |
|
|
2022
Q4 | $644K | Sell |
13,927
-1,378
| -9% | -$59.7K | ﹤0.01% | 847 |
|
|
2022
Q3 | $593K | Buy |
15,305
+3,723
| +32% | +$149K | ﹤0.01% | 816 |
|
|
2022
Q2 | $432K | Sell |
11,582
-291
| -2% | -$11.8K | ﹤0.01% | 880 |
|
|
2022
Q1 | $526K | Buy |
11,873
+941
| +9% | +$40.8K | ﹤0.01% | 845 |
|
|
2021
Q4 | $464K | Sell |
10,932
-549
| -5% | -$23.1K | ﹤0.01% | 900 |
|
|
2021
Q3 | $498K | Buy |
11,481
+180
| +2% | +$7.96K | ﹤0.01% | 828 |
|
|
2021
Q2 | $483K | Buy |
11,301
+1,146
| +11% | +$48.2K | ﹤0.01% | 849 |
|
|
2021
Q1 | $393K | Sell |
10,155
-24
| -0.2% | -$908 | ﹤0.01% | 888 |
|
|
2020
Q4 | $366K | Sell |
10,179
-12,976
| -56% | -$468K | ﹤0.01% | 840 |
|
|
2020
Q3 | $885K | Buy |
23,155
+967
| +4% | +$37.3K | ﹤0.01% | 635 |
|
|
2020
Q2 | $779K | Buy |
22,188
+3,618
| +19% | +$130K | ﹤0.01% | 649 |
|
|
2020
Q1 | $606K | Sell |
18,570
-1,541
| -8% | -$60.2K | ﹤0.01% | 649 |
|
|
2019
Q4 | $910K | Buy |
20,111
+340
| +2% | +$14.2K | ﹤0.01% | 652 |
|
|
2019
Q3 | $804K | Sell |
19,771
-213
| -1% | -$9.02K | ﹤0.01% | 658 |
|
|
2019
Q2 | $858K | Sell |
19,984
-81,316
| -80% | -$3.13M | ﹤0.01% | 664 |
|
|
2019
Q1 | $3.89M | Buy |
101,300
+2,800
| +3% | +$107K | 0.01% | 492 |
|
|
2018
Q4 | $3.48M | Sell |
98,500
-61,909
| -39% | -$2.25M | 0.01% | 481 |
|
|
2018
Q3 | $6.18M | Sell |
160,409
-2,454
| -2% | -$85.7K | 0.02% | 407 |
|
|
2018
Q2 | $5.33M | Buy |
162,863
+143,193
| +728% | +$4.32M | 0.02% | 429 |
|
|
2018
Q1 | $537K | Sell |
19,670
-33,600
| -63% | -$913K | ﹤0.01% | 819 |
|
|
2017
Q4 | $1.32M | Sell |
53,270
-7,181
| -12% | -$198K | ﹤0.01% | 610 |
|
|
2017
Q3 | $1.76M | Buy |
60,451
+1,771
| +3% | +$48.9K | 0.01% | 535 |
|
|
2017
Q2 | $1.63M | Buy |
58,680
+50,279
| +598% | +$1.33M | 0.01% | 562 |
|
|
2017
Q1 | $208K | Buy |
+8,401
| New | +$204K | ﹤0.01% | 1099 |
|
Other funds holding BSX
Brown Advisory's BSX Position: Q2 2026 in Review
Brown Advisory reduced its Boston Scientific (BSX) stake by 45% in Q2 2026, selling an estimated $495K and leaving 11,180 shares worth $477K. The position accounts for ﹤0.01% of the portfolio, ranked #1148.
Brown Advisory first reported a position in BSX in Q1 2017 and has held it in 38 quarters since. The position peaked at $6.18M in Q3 2018. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Brown Advisory held 11,180 shares of Boston Scientific worth $477K as of Q2 2026.
- Brown Advisory sold 9,120 Boston Scientific shares in Q2 2026, an estimated $495K.
- Boston Scientific made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #1148 holding.
- Brown Advisory first reported a position in Boston Scientific in Q1 2017 and has held it in 38 quarters since.
- Brown Advisory's Boston Scientific position peaked at $6.18M in Q3 2018.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.